MOH — authorised 16 June 2023
- Marketing authorisation holder: SPECTRUM PHARMS
- Status: likely_approved
MOH authorised ROLVEDON on 16 June 2023
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Yes. MOH authorised it on 16 June 2023.
SPECTRUM PHARMS holds the UAE marketing authorisation.